Hims & Hers Health has struck a deal with Eli Lilly allowing patients to buy Lilly's GLP-1 medications, including the popular Zepbound injection and Foundayo pill, directly through Hims & Hers' telehealth platform. Previously, patients had to use Lilly's own telehealth service to purchase these drugs. As part of the agreement, Hims & Hers will stop compounding GLP-1 medications like Zepbound in the future. This move streamlines access for patients and could boost Hims & Hers' position in the weight-loss treatment market.
Hims & Hers Health shares are up 5.65% at USD 25.42 on Pluang, showing strong investor interest following the GLP-1 deal with Eli Lilly. Eli Lilly's stock is relatively stable, trading at USD 1,369.14 with a slight 0.10% increase as of Nov 06, 2026 23:41 WIB.
